ADT	Androgen deprivation therapy
ALS	Acid-labile subunit
ASOs	Antisense oligonucleotides
BAD	Bcl-2-associated agonist of cell death
BCR	Biochemical recurrence
BPH	Benign prostatic hyperplasia
C-NHEJ	Classical nonhomologous end joining
CRPC	Castration-Resistant Prostate Cancer
DSBs	Double-strand breaks
ECM	Extracellular matrix
EMT	Epithelial-mesenchymal transition
FOXA1	Forkhead box A1
FOXOs	Forkhead box transcription factors
GS	Gleason score
GSK3α/β	Glycogen synthase kinase-3α/β
HIF-1α	Hypoxia-inducible factor-1α
HR	Homologous recombination
IGF-1	Insulin-like growth factor-1
IGFBPs	Insulin-like growth factor binding proteins
IGF-1R	Insulin-like growth factor-1 receptor
INSR	Insulin receptor
mAb	Monoclonal antibody
mHSPC	Metastatic castration-sensitive prostate cancer
MDR	Multidrug resistance
MMP	Matrix metalloproteinase
OR	Odds ratio
OS	Overall Survival
PCa	Prostate cancer
PFS	Progression-free survival
PSA	Prostate-specific antigen
PTEN	Gene of phosphate and tensin homolog deleted on chromosome ten
RR	Relative risk
siRNA	Small-interfering RNA
Src	Sarcoma gene
TCF/LEF	T-cell factor/lymphoid enhancer factors
TRAMP	Transgenic adenocarcinoma of mouse prostate
TUBB2B	β-tubulin isoform 2B
VEGF	Vascular endothelial growth factor